| Quality assessment | | | | | | | No of patients | | Effect | | | |
|-------------------------------------|--------------------------|--------------------------------|-----------------------------|----------------------------|----------------------|----------------------|--|--|------------------------------|---|-------------|------------|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Short course RT: 8 Gy in 1 day, 5x 4 Gy in 1 week | Long course RT: 10x 3 Gy in 2weeks 15x 25Gy in 3 weeks, 20x 2Gy in 4weeks | Relative (95% CI) | Absolute | Quality | Importance |
| Pain | | | | | | | | | | | | |
| | No evidence available | | | | | none | - | - 0% | - | - | | CRITICAL |
| Reter mo | otor function | | | | | | | 078 | | - | | |
| 1 | observational studies | very serious ^{1,2} | no serious inconsistency | no serious indirectness | serious ³ | none | 32/114 (28.1%) | 35/117 (29.9%) | RR 0.99 (0.81 to 1.22) | 1.84 fewer per 100 (from 13.54 fewer to 9.86 more) | VERY LOW | CRITICAL |
| | | | | | | | | 0% | | - | | |
| No chang | ge in motor fun | nction | | | | | | | | | | |
| | observational studies | very serious ^{1,2} | no serious inconsistency | no serious indirectness | serious ³ | none | 70/114 (61.4%) | 72/117 (61.5%) | RR 0.99 (0.81 to 1.22) | 0.14 fewer per 100 (from 12.69 fewer to 12.42 more) | VERY LOW | CRITICAL |
| Pasnana | duration lask | of MSCC | recurrence at 12 | months | | | | 0% | | - | | |
| 1 | observational | very | no serious | no serious indirectness | serious ³ | none | 62/102 (60.8%) | 84/109 (77.1%) | RR 0.79 (0.65 to 0.95) | 16.28 fewer per 100 (from 16.28 fewer to 3.95 fewer) | VERY LOW | CRITICAL |
| T! - !4 | | <u> </u> | | | | | | 0% | | - | | |
| - | No evidence available | | | | | none | - | - 0% | - | - | | CRITICAL |
| Progression Free Survival- 6 months | | | | | | | | | | | | |
| 1 | observational | very | no serious | no serious indirectness | serious ³ | none | 77/114 (67.5%) | 101/117 (86.3%) | RR 0.78 (0.68 to | 18.8 fewer per 100 (from 29.4 fewer to | | IMPORTANT |

| | | | | | | | | | 0.91) | 8.17 fewer) | LOW | |
|--------------------------------------|--------------------------|---|--|----------------------------|----------------------|------|-------------------|-------------------|-------|--|-----|-----------|
| | | | | | | | | 0% | | - | | |
| Progression free survival- 12 months | | | | | | | | | | | | |
| 1 | observational studies | , | | no serious indirectness | serious ³ | none | 63/114 (55.3%) | 84/117 (71.8%) | | 16.5 more per 100 (from 4.29 more to 28.7 more) ⁴ | | IMPORTANT |
| | | | | | | | | 0% | | - | | |
| Bladder function | | | | | | | | | | | | |
| 0 | No evidence | | | | | none | - | - | - | - | | IMPORTANT |
| | available | | | | | | | 0% | | - | | |

¹ one cohort The Netherlands, one cohort Germany

² no blinding reported

³ low number of patients and the confidence interval crossed the clinical decision threshold between the short course Radiotherapy and long course Radiotherapy

⁴ RR and Risk difference is long course vs short course (instead of short course vs long course)